Normalized adjusted EBITDA(1) remained relatively stable at $59.4 million in the quarter, compared to $60.4 million in Q4-23.System sales(2) for ...
Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...
Trump's de minimis delay leaves DTC brands in turmoil, struggling to plan amid sudden policy changes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback